Orthobiologics

Histogenics has completed >50% of the required enrollment in its ongoing NeoCart® Phase III clinical trial in the treatment of knee cartilage defects....

Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. ...

BONESUPPORT expanded its 2014 injectable bone substitute registry to include 230 CERAMENT™ G procedures, as well as procedures involving the CERAMENT V...

In late 2015, FDA assigned Anika Therapeutics' CINGAL to the Center for Drug Evaluation and Research (CDER) and not the...

AlloSource was awarded U.S. Patent No. 9,186,253, Cartilage mosaic compositions and methods, for its ProChondrix® Cartilage Restoration Matrix allograft product....

Bone Therapeutics commenced a Phase IIA study for the treatment of multiple delayed-union fractures with ALLOB® allogeneic bone cell therapy...

BONESUPPORT announced the milestone of >20,000 patients treated worldwide to date with CERAMENT™ injectable drug-eluting bone substitute products....

Bioventus launched DUROLANE® single-injection hyaluronic acid-based osteoarthritis treatment in Taiwan....

Vericel submitted a Biologics License Application to FDA for MACI™ matrix applied characterized autologous cultured chondrocytes, an investigational product intended...